Sirolimus and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Sirolimus (sirolimus), especially for people who are male, 50-59 old, have been taking the drug for 6 - 12 months also take Mycophenolate Mofetil, and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Sirolimus. It is created by eHealthMe based on reports of 11,812 people who have side effects when taking Sirolimus from the FDA, and is updated regularly.

What is Sirolimus?

Sirolimus has active ingredients of sirolimus. eHealthMe is studying from 11,823 Sirolimus users. Check the latest studies of Sirolimus.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 591 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 11, 2026

11,812 people reported to have side effects when taking Sirolimus.
Among them, 39 people (0.33%) have Progressive multifocal leukoencephalopathy.

Could Sirolimus cause Progressive multifocal leukoencephalopathy?

Among these 39 people:

How long have people been on Sirolimus when they have Progressive multifocal leukoencephalopathy? *

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Sirolimus? *

female: 31.43 %
male: 68.57 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Sirolimus? *

What are other drugs people take besides Sirolimus? *

Mycophenolate Mofetil: 16 people, 41.03%
Tacrolimus: 13 people, 33.33%
Cyclosporine: 7 people, 17.95%
Busulfan: 6 people, 15.38%
Cytarabine: 6 people, 15.38%
Fludarabine Phosphate: 6 people, 15.38%
Nifedipine: 5 people, 12.82%
Prednisone: 5 people, 12.82%
Thiotepa: 4 people, 10.26%
Voriconazole: 3 people, 7.69%

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Jc Virus Infection: 16 people, 41.03%
Weakness: 5 people, 12.82%
Cytomegalovirus Viraemia (cytomegalo virus in blood stream): 5 people, 12.82%
Iiird Nerve Disorder: 4 people, 10.26%
Epstein-Barr Viraemia: 4 people, 10.26%
Neurological Decompensation (inability of brain to maintain proper function): 4 people, 10.26%
Myoclonus (a brief, involuntary twitching of a muscle or a group of muscles): 4 people, 10.26%
Staphylococcal Infection (an infection with staphylococcus bacteria): 4 people, 10.26%
Cranial Nerve Disorder (impaired functioning of one of the twelve cranial nerves): 4 people, 10.26%
Central Nervous System Lesion (an abnormality in tissue of brain or spinal cord): 4 people, 10.26%

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 15 people, 38.46%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 14 people, 35.90%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 7 people, 17.95%
Thrombotic Thrombocytopenic Purpura (a rare blood disorder characterized by clotting in small blood vessels of the body): 7 people, 17.95%
Chronic Graft Versus Host Disease In Skin (damage by immune cells to skin after grafting): 6 people, 15.38%
Kidney Transplant Rejection: 5 people, 12.82%
Bone Marrow Conditioning Regimen: 5 people, 12.82%
Cutaneous Vasculitis (an inflammatory process affecting the vessel wall that leads to its damage): 4 people, 10.26%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 5.13%
Immunodeficiency Disorders: 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Sirolimus and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sirolimus:

Sirolimus (11,823 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Sirolimus

Expand to all the drugs that have ingredients of sirolimus:

Progressive multifocal leukoencephalopathy and drugs with ingredients of sirolimus (45 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sirolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (591 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sirolimus (the active ingredients of Sirolimus) and Sirolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.